Biblio

Found 359 results
[ Author(Asc)] Keyword Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
J. B. Vermorken, Optimal treatment for ovarian cancer: taxoids and beyond., Ann Oncol, vol. 11 Suppl 3, pp. 131-9, 2000.
J. B. Vermorken, Parmar, M. K. B., Brady, M. F., Eisenhauer, E., Högberg, T., Ozols, R. F., Rochon, J., Rustin, G. J. S., Sagae, S., and Verheijen, R. H. M., Clinical trials in ovarian carcinoma: study methodology., Ann Oncol, vol. 16 Suppl 8, pp. viii20-viii29, 2005.
J. B. Vermorken, Parmar, M. K. B., Brady, M. F., Eisenhauer, E., Högberg, T., Ozols, R. F., Rochon, J., Rustin, G. J. S., Sagae, S., Verheijen, R. H. M., InterGroup, G. Cancer, ,, /NCRI, M. R. C., ,, -CTG, N. C. I. C., ,, -OVAR, A. G. O., and , Clinical trials in ovarian carcinoma: study methodology, Ann Oncol, vol. 16 Suppl 8, pp. viii20-viii29, 2005.
J. B. Vermorken, The role of intraperitoneal chemotherapy in epithelial ovarian cancer., Int J Gynecol Cancer, vol. 10, no. S1, pp. 26-32, 2000.
L. Verleye, Coens, C., Amant, F., van der Burg, M. E. L., Johnson, N., Verheijen, R. H. M., Coronado, P., Reed, N. Simon, RJ, P., and Vergote, I. B., Predictive value of C-ERB2 for response to first-line chemotherapy in 206 advanced-stage ovarian cancer patients. , Int Gyn Cancer Soc, 2008.
L. Verleye, PB, O., Coens, C., Amant, F., Kristensen, G. B., Tropé, C. G., Johnson, N., HC, vanDoorn, Reed, N. Simon, Verheijen, R. H. M., Hoskins, P., Trimbos, B., B, M., Mendiola, C., J, vander Velden, Eisenhauer, E., and Vergote, I. B., Quality of surgery in advanced ovarian cancer: Audit of original surgery reports of 442 patients from the neoadjuvant trial. , Int Gyn Cancer Soc, 2008.
I. B. Vergote, Jimeno, A., Joly, F., Katsaros, D., Coens, C., Despierre, E., Marth, C., Hall, M., Steer, C. B., Colombo, N., Lesoin, A., Casado, A., Reinthaller, A., Green, J. A., Buck, M., Ray-Coquard, I., Ferrero, A., Favier, L., Reed, N. Simon, Curé, H., and Pujade-Lauraine, E., Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a EORTC GCG, and GCIG study., J Clin Oncol, vol. 32, no. 4, pp. 320-6, 2014.
I. B. Vergote, Rustin, G. J. S., Eisenhauer, E., Kristensen, G. B., Pujade-Lauraine, E., Parmar, M. K. B., Friedlander, M. Leonard, Jakobsen, A., and Vermorken, J. B., Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup., J Natl Cancer Inst, vol. 92, no. 18, pp. 1534-5, 2000.
I. B. Vergote, Calvert, A. H., Kania, M., Kaiser, C., Zimmermann, A. Hayden, and Sehouli, J., A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer, Eur J Cancer, vol. 45, pp. 1415-23, 2009.
I. B. Vergote, Organization and ethical aspects of randomized trials in gynecologic oncology, Verh K Acad Geneeskd Belg, vol. 62, pp. 385-95; discussion 395-8, 2000.
I. B. Vergote, Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. Benedetti, Kenter, G. G., Casado, A., Mendiola, C., Coens, C., Verleye, L., Stuart, G. C. E., Pecorelli, S., and Reed, N. Simon, Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer., N Engl J Med, vol. 363, no. 10, pp. 943-53, 2010.
G. F. Vercellino, Erdemoglu, E., Lichtenberg, P., Muallem, M. Z., Richter, R., Abu-Rustum, N. R., Plante, M., Lécuru, F., Greggi, S., Monk, B. J., Sagae, S., Denkert, C., Keller, M., Alhakeem, M., Hellriegel, M., Dückelmann, A. M., Chiantera, V., and Sehouli, J., A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer., Arch Gynecol Obstet, 2019.
P. A. Vasey, Jayson, G. C., Gordon, A., Gabra, H., Coleman, R. L., Atkinson, R. J., Parkin, D., Paul, J., Hay, A., Kaye, S. B., and Group, S. Gynaecolog, Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma, J Natl Cancer Inst, vol. 96, pp. 1682-91, 2004.
P. A. Vasey, Gore, M. E., Wilson, R. H., Rustin, G. J. S., Gabra, H., Guastalla, J. P., Lauraine, E. P., Paul, J., Carty, K., Kaye, S. B., and Group, S. Gynaecolog, A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers, Br J Cancer, vol. 98, pp. 1774-80, 2008.
P. A. Vasey, Atkinson, R. J., Osborne, R., Parkin, D., Symonds, R., Paul, J., Lewsley, L. A., Coleman, R. L., Reed, N. Simon, Kaye, S. B., and Rustin, G. J. S., SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer, Br J Cancer, vol. 94, pp. 62-8, 2006.
F. H. van Wijk, Aapro, M. S., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A. M., de Oliveira, C. F., Tumolo, S., V. di Palumbo, S., Piccart, M. J., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M. A., Presti, M., Scarabelli, C., Splinter, T. A., Ploch, E., Beex, L. V., Huinink, W. W. ten Bok, Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E., Teodorovic, I., Coens, C., Vergote, I. B., Vermorken, J. B., Research, E. Organisati, and Group, Tof Cancer, Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group, Ann Oncol, vol. 14, pp. 441-8, 2003.
F. H. van Wijk, Aapro, M. S., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A. M., de Oliveira, C. F., Tumolo, S., V. di Palumbo, S., Piccart, M. J., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M. A., Presti, M., Scarabelli, C., Splinter, T. A. W., Ploch, E., Beex, L. V., Huinink, W. W. ten Bok, Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E. G. M., Teodorovic, I., Coens, C., Vergote, I. B., and Vermorken, J. B., Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group., Ann Oncol, vol. 14, no. 3, pp. 441-8, 2003.
M. E. L. van der Burg, Myles, J., Hoskins, P., W, T. Bokkel- Hui, and Eisenhauer, E., CA-125 is an unreliable marker for monitoring response to taxol therapy in patients with relapsed ovarian cancer. , Eur.J.Can. , vol. 29A, no. Suppl.6, 1993.
M. E. L. van der Burg, van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., and Pecorelli, S., The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer, N Engl J Med, vol. 332, pp. 629-34, 1995.
T
D. Trudel, Desmeules, P., Turcotte, S., Plante, M., Gregoire, J., Renaud, M. C., Orain, M., Bairati, I., and Tetu, B., Visual and automated assessment of matrix metalloproteinase-14 tissue expression for the evaluation of ovarian cancer prognosis, Mod Pathol, 2014.
J. B. Trimbos, Vergote, I. B., Bolis, G., Vermorken, J. B., Mangioni, C., Madronal, C., Franchi, M., Tateo, S., Zanetta, G., Scarfone, G., Giurgea, L., Timmers, P., Coens, C., Pecorelli, S., Collaborators, E. O. R. T. C. - A. C. T. I. O. N., Research, E. Organisati, and Neoplasm, Tof Cancer-, Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial, J Natl Cancer Inst, vol. 95, pp. 113-25, 2003.
J. B. Trimbos, Parmar, M. K. B., Vergote, I. B., Guthrie, D., Bolis, G., Colombo, N., Vermorken, J. B., Torri, V., Mangioni, C., Pecorelli, S., Lissoni, A., Swart, A. Marie, Neoplasm, I. Collaborat, Research, E. Organisati, and Neoplasm, Tof Cancer, International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma, J Natl Cancer Inst, vol. 95, pp. 105-12, 2003.
B. Trimbos, Timmers, P., Pecorelli, S., Coens, C., Ven, K., van der Burg, M. E. L., and Casado, A., Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial., J Natl Cancer Inst, vol. 102, no. 13, pp. 982-7, 2010.
E. L. Trimble, Ledermann, J. A., Law, K., Miyata, T., Imamura, C. K., Nam, B. - H., Kim, Y. H., Bang, Y. - J., Michaels, M., Ardron, D., Amano, S., Ando, Y., Tominaga, T., Kurokawa, K., and Takebe, N., International models of investigator-initiated trials: implications for Japan., Ann Oncol, vol. 23, no. 12, pp. 3151-5, 2012.

Pages